Novel oral combination chemotherapy in the treatment of intermediate-grade and high-grade AIDS-related non-Hodgkin's lymphoma.

Abstract

This regimen is active in patients with AIDS-related non-Hodgkin's lymphoma. Because it is important to design systemic cytotoxic chemotherapy regimens that are cost-effective, considerate of quality-of-life issues, and efficacious in this patient population, this approach should be compared with standard intravenous combination chemotherapy regimens in randomized controlled clinical trials.

Treatment factors affecting outcomes in HIV-associated non-Hodgkin lymphomas: a pooled analysis of 1546 patients

“…The variables of interest were the use of rituximab with chemotherapy, the type of chemotherapy defined as either (1) (2) cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP), (3) modified or low-dose CHOP, (4) infusional etoposide, prednisone, infusional vincristine, infusional doxorubicin, and cyclophosphamide (EPOCH), (5) vincristine and steroid (VS), (6) doxorubicin, cyclophosphamide, vindesine, bleomycin, and prednisolone (ABCVP) or LNHIV91 (for detailed description, see the original publication 24 ), (7) infusional cyclophosphamide, doxorubicin, and etoposide (CDE), and (8) the oral regimen lomustine, etoposide, cyclophosphamide and procarbazine (Remick regimen), 25 concurrent use of cART, and supportive use of granulocyte-colony-stimulating factor (G-CSF). Additionally, we grouped the chemotherapeutic regimens based on their relative intensity compared with CHOP for parts of the analysis as follows: less dose-intense regimens (VS, Remick regimen, modified, and/or low-dose CHOP) and doseintense regimens (ACVBP and intensive regimens).…”

High dose therapy and autologous stem cell transplantation for human immunodeficiency virus-associated non-Hodgkin lymphoma in the era of highly active antiretroviral therapy

“…The administration of chemotherapy to patients with HIV-related lym-phoma also is associated with a significant and sustained reduction in CD4 lymphocyte counts and severe neutropenia, leading to treatment delays despite the use of G-CSF. [32][33][34] Currently, issues regarding the optimal combination chemotherapy regimen for the treatment of patients with HIV-related NHL as well as the dose intensity and route of administration of the chosen regimen remain largely undefined. Few studies have assessed prospectively the impact of combined single-agent antiretroviral therapy and standard chemotherapy as front-line therapy for patients with HIVrelated lymphoma.…”

HIV-Associated lymphomas

“…The results with this regimen were comparable with those in other combinations (CR, 39%; median survival, 7 months). Toxicities aside from myelosuppression were mild, and the costs were less than those for standard-dose CHOP or m-BACOD [23].…”